Cancer Network Faceoff: Conclusion of the Event and Presentation of Awards
Conclusion of the discussion and award presentation.
Optimal Approach for PD-L1 >50%
Discussion regarding immunotherapy alone or in combination with chemotherapy for patients with NSCLC that are PD-L1 >50%.
Treatment for Borderline Resectable Patients With NSCLC
Discussion on the treatment for borderline resectable patients with NSCLC.
Will Combination Therapies Replace Osimertinib Monotherapy as Standard-of-Care in Frontline EGFR-Mutant Advanced NSCLC?
Osimertinib monotherapy as the standard of treatment for frontline EGFR mutant advanced NSCLC will be replaced by combination therapies.
Adjuvant Osimertinib for Resected EGFR Mutated Stage IB-IIIA Non-Small Cell Lung Cancer
EGFR-mutated stage IB-IIIA non-small cell lung carcinoma that has been removed and treated with adjuvant osimertinib.
Brigatinib Versus Crizotinib in ALK inhibitor-Naïve Advanced ALK-Positive NSCLC: Results of Phase 3 ALTA-1L Trial
Results of phase 3 ALTA-1L study comparing crizotinib with Brigatinib in advanced ALK-positive non-small cell lung cancer
Introduction of the Debate Between Jets v. Giants
An outline of the debate, the speakers, and the basic guidelines to support the program.